Combinations Alliance EOI Calls - Astex

Astex Expression of Interest Call - open till 30th May, 2014 

We are delighted to announce that Astex Pharmaceuticals have joined the Combinations Alliance. Astex are the third pharma partner to offer their agents to the ECMC Network through this initiative and we look forward to a successful collaboration with them.

In the first instance, Astex are offering two agents from their early phase portfolio:

• AT13387 (a novel potent non-ansamycin HSP90 inhibitor)
• SGI-110 (a novel subcutaneous second generation hypomethylating agent).

Combination studies with other novel agents, standard of care or radiotherapy are sought. If the novel agents you plan to combine either of these Astex agents with are not currently available within the Combinations Alliance Portfolio, we will contact companies of interest on your behalf (although timeline will be longer). This will also shape the strategy for expanding the ECMC Combinations Alliance portfolio. We would also welcome EOI proposals involving Astex agents that may require additional preclinical work. These proposals will be discussed with Astex with opportunities for direct funding or application to the NAC preclinical funding stream.

Astex presented their data for both of these compounds on Tuesday April 22nd. You can listen to the webinar here.

We hope this will be of interest to the ECMC network and look forward to receiving your EOIs.

Summary of Key Dates